… The discovery of LY-CoV555 and its passive protection against SARS-CoV-2 in nonhuman
… LY-CoV555 or placebo was administered within 3 days after positive results on SARS-CoV-2 …

… LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-…
Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts …

… (10) LY-CoV555 was observed to bind to an epitope … (5, 20, 21) Based on the crystal structure,
the LY-CoV555 epitope … of LY-CoV555 Fab complexes in which the LY-CoV555 Fab was …

… LY-CoV016). In addition, the L452R mutation in the B.1.429 lineage escapes LY-CoV555.
Furthermore, we identify single amino acid changes that escape the combined LYCoV555+LY-…

… /LY-CoV555) for the treatment of mild-to-moderate COVID-19. This review outlines the
development of neutralizing antibodies against SARS-CoV-… of SARS-CoV-2 and SARS-CoV might …

… combination of LY-CoV555 and LY-… LY-CoV555 monotherapy and placebo. Citation22
Preliminary results of the BLAZE-1 study, provided only for the comparison between LY-CoV555 …

… (mAb) bamlanivimab (LY-CoV555) prevents viral attachment … , showing that LY-CoV555 is
ineffective against B.1.351 but is … bamlanivimab (LY-CoV555) using live SARS-CoV-2 isolates. …

… Of these, LY-CoV555 is the first antibody to enter into phase 1 clinical trials in the world
and the NAb CB6, termed as JS016 in the clinical trial, is in the steady progress of phase 1 in …

… SARS-CoV-2 but failed to target the Kappa variant. Here, we focus on the drug LY-CoV555
that … LY-CoV555 recognizes an epitope site in the RBD overlapping the binding site of hACE2 …

… Mice treated with 2B04/47D11 or LY-CoV555 also showed greater virus breakthrough than
… than the other mAb cocktails, and LY-CoV555 mAb treatment conferred virtually no protection …